


EPA's Path Towards More Rapid, Efficient, and Protective Chemical Testing with Fewer Animals



Superfund Research Program 2020 Annual Meeting


December 15, 2020

Rusty Thomas
Director
Center for Computational Toxicology and Exposure

The views expressed in this presentation are those of the presenter and do not necessarily reflect the views or policies of the U.S. EPA

The EPA Needs to Make A Range of Decisions on Chemicals


- Decisions on the manufacture, use, release, disposal, and clean-up of chemicals is governed by a range of statutes and associated amendments
 - e.g., Safe Drinking Water Act, Clean Air Act, Toxic Substances Control Act, Food Quality Protection Act
- The statutes provide the framework for the decisions while Agency rules and guidance outline the interpretation of the statutes and how decisions are implemented
- Different decision contexts exist within the statutes, which determine the type of data and level of certainty required
 - Prioritization (e.g., EDSP, TSCA)
 - Emergency response (e.g., AEGLs)
 - Screening-level assessments (e.g., CCL, PMN)
 - Provisional assessments (e.g., PPRTVs)
 - Toxicity assessments (e.g., IRIS)
 - Endangered species protection (e.g., pesticides)
 - Risk assessments (e.g., MCLs, pesticides, TSCA risk evaluations)



There is a Lack of Data on Hazard, Toxicokinetics, and Exposure for Most Chemicals


Hazard

Percentage of Non-Confidential, Active TSCA Inventory with Repeat Dose Toxicity Studies




Data from ToxValDB (Dec 2019)

Exposure




Egeghy et al., Science of the Total Environment, 2012



Toxicokinetics



There are Large Numbers of Chemicals on Various National Inventories




The Costs and Time Associated with Traditional Testing and Assessment are Extensive



- Time from chemical selection to completion of subchronic and chronic tox studies requires 2+ years
- Time to perform a typical chemical assessment is 4+ years (Krewski et al., 2020)

EPA Intends to Overcome these Challenges while Reducing Animal Testing



○ Aims to:

- Reduce requests for, and funding of, mammalian studies by 30% by 2025
- Eliminate all mammalian study requests and funding by 2035
- Come as close as possible to excluding reliance on mammalian studies from its approval process (subject to applicable legal requirements).
- Achieve reduction in animal use through the development and application of New Approach Methods (NAMs)

○ Work Plan includes:

- Evaluating regulatory flexibility for accommodating NAMs
- Develop baselines and metrics for assessing progress
- Establish scientific confidence in NAMs and demonstrate application to regulatory decisions
- Develop NAMs to address scientific challenges and fill important information gaps
- Engage and communicate with stakeholders

Multiple Opportunities Exist for Research in the SRP to Contribute



Establish
scientific
confidence and
demonstrate
application



Develop NAMs
that fill critical
information
gaps

- The EPA NAM work plan explicitly encourages development and evaluation of NAMs by external parties
 - More rapidly closes important information gaps and accelerates movement toward achieving the overall goals.
 - Increase acceptance of new methods
- Superfund research program has a long history in developing methods that can help inform decisions on chemicals and demonstrating application

The Development and Integration of NAMs is a Key Component in Achieving the Goals

SOT | Society of
Toxicology
www.toxsci.oxfordjournals.org

TOXICOLOGICAL SCIENCES, 169(2), 2019, 317–332
doi: 10.1093/toxsci/kfz058
Advance Access Publication Date: March 5, 2019
Forum

FORUM

The Next Generation Blueprint of Computational Toxicology at the U.S. Environmental Protection Agency

Russell S. Thomas,^{*1} Tina Bahadori,[†] Timothy J. Buckley,[‡] John Cowden,^{*} Chad Deisenroth,^{*} Kathie L. Dionisio,[‡] Jeffrey B. Frithsen,[§] Christopher M. Grulke,^{*} Maureen R. Gwinn,^{*} Joshua A. Harrill,^{*} Mark Higuchi,[¶] Keith A. Houck,^{*} Michael F. Hughes,[¶] E. Sidney Hunter, III,[¶] Kristin K. Isaacs,[‡] Richard S. Judson,^{*} Thomas B. Knudsen,^{*} Jason C. Lambert,^{||} Monica Linnenbrink,^{*} Todd M. Martin,^{||} Seth R. Newton,[‡] Stephanie Padilla,[¶] Grace Patlewicz,^{*} Katie Paul-Friedman,^{*} Katherine A. Phillips,[‡] Ann M. Richard,^{*} Reeder Sams,^{*} Timothy J. Shafer,[¶] R. Woodrow Setzer,^{*} Imran Shah,^{*} Jane E. Simmons,[¶] Steven O. Simmons,^{*} Amar Singh,^{*} Jon R. Sobus,[‡] Mark Strynar,[‡] Adam Swank,[‡] Rogelio Tornero-Valez,[‡] Elin M. Ulrich,[‡] Daniel L. Villeneuve,^{||} John F. Wambaugh,^{*} Barbara A. Wetmore,[‡] and Antony J. Williams^{*}

^{*}National Center for Computational Toxicology, U.S. Environmental Protection Agency, Research Triangle Park, NC 27711, [†]National Center for Environmental Assessment, U.S. Environmental Protection Agency, Washington, D.C. 20004, [‡]National Exposure Research Laboratory, U.S. Environmental Protection Agency, Research Triangle Park, NC 27711, [§]Chemical Safety for Sustainability National Research Program, U.S. Environmental Protection Agency, Washington, D.C. 20004, [¶]National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency, Research Triangle Park, NC 27711, ^{||}National Center for Environmental Assessment, U.S. Environmental Protection Agency, Cincinnati, OH 45220, ^{||}National Risk Management Research Laboratory, U.S. Environmental Protection Agency, Cincinnati, OH 45220, and ^{||}National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency, Duluth, MN 55804

[†]To whom correspondence should be addressed at National Center for Computational Toxicology, Office of Research and Development, U.S. Environmental Protection Agency, 109 T.W. Alexander Drive, Room D110-D, Mail Code: D143-02, Research Triangle Park, NC 27711. Fax: (919) 541-1194. E-mail: thomas.russell@epa.gov


Disclaimer: The U.S. Environmental Protection Agency has provided administrative review and has approved this article for publication. The views expressed in this article are those of the authors and do not necessarily reflect the views of the U.S. Environmental Protection Agency.

ABSTRACT

The U.S. Environmental Protection Agency (EPA) is faced with the challenge of efficiently and credibly evaluating chemical safety often with limited or no available toxicity data. The expanding number of chemicals found in commerce and the environment, coupled with time and resource requirements for traditional toxicity testing and exposure characterization,

Published by Oxford University Press on behalf of the Society of Toxicology 2019.
This work is written by US Government employees and is in the public domain in the US.

317





- High-throughput and high-content screening
- Tiered testing
- Organotypic models



- HTTK assays
- IVIVE methods and models

- Consensus exposure models
- NTA/SSA


Developing High-Throughput Phenotypic Profiling Methods to Evaluate Effects in Multiple Human Cell Types




Expanding High-Throughput Transcriptomic Assays to Evaluate Volatile Chemicals




Whole Genome Transcriptomics (HTTr)



Mode-of-Action Identification



Concentration Response Modeling




	ACGIH TLV-TWA (ppm)	BEAS-2B HTTr POD (ppm)	HBEC HTTr POD (ppm)
Acrolein	0.1	0.58	--
Formaldehyde	0.3	NA	--
1,3-Butadiene	10	13.98	--
Acetaldehyde	25	NA	--
1-Bromopropane	0.1 *	2.25	NA
Carbon Tetrachloride	10	9.56	NA
Trichloroethylene	50	44.8	28.1
Dichloromethane	100	142.13	266.7


* The ACGIH TLV TWA for 1-bromopropane was updated to 0.1 ppm in 2012. Prior to that the TLV-TWA for 1-bromopropane was 10 ppm.

A.Speen (CPHEA), M. Higuchi
(CPHEA), and J. Harrill,
Unpublished

Developing Organotypic Culture Models to Identify Tissue/Organ Effects




Developing and Improving High-Throughput Toxicokinetic Assays and Modeling Approaches



Liver Metabolism Tissue Partitioning Plasma Protein Binding

Population-Based
IVIVE Model

Oral Dose Required to
Achieve Concentrations
Equivalent to *In Vitro*
Bioactivity




R package “httk”


- Open source, transparent, and peer-reviewed tools and data for **high throughput toxicokinetics (httk)**
- Allows *in vitro-in vivo* extrapolation (IVIVE) and physiologically-based toxicokinetics (PBTk)
- Human-specific data for 987 chemicals
- Allows propagation of uncertainty

Rotroff *et al.*, *Tox Sci.*, 2010
Wetmore *et al.*, *Tox Sci.*, 2012
Wetmore *et al.*, *Tox Sci.*, 2015
Wambaugh *et al.*, *Tox Sci.*, 2018
Wambaugh *et al.*, *Tox Sci.*, 2019
Linakis *et al.*, *J Expo Sci Environ Epidemiol.* 2020
G. Honda and J. Wambaugh,
Unpublished

Improving Oral PK Models





Incorporating Generic Inhalation PBPK Model




Developing and Improving High-Throughput Exposure Modeling Approaches


Predictor	Reference(s)	Chemicals Predicted	Pathways
EPA Inventory Update Reporting and Chemical Data Reporting (CDR) (2015)	US EPA (2018)	7856	All
Stockholm Convention of Banned Persistent Organic Pollutants (2017)	Lallas (2001)	248	Far-Field Industrial and Pesticide
EPA Pesticide Reregistration Eligibility Documents (REDs) Exposure Assessments (Through 2015)	Wetmore et al. (2012, 2015)	239	Far-Field Pesticide
United Nations Environment Program and Society for Environmental Toxicology and Chemistry toxicity model (USEtox) Industrial Scenario (2.0)	Rosenbaum et al. (2008)	8167	Far-Field Industrial
USEtox Pesticide Scenario (2.0)	Fantke et al. (2011, 2012, 2016)	940	Far-Field Pesticide
Risk Assessment IDentification And Ranking (RAIDAR) Far-Field (2.02)	Arnot et al. (2008)	8167	Far-Field Pesticide
EPA Stochastic Human Exposure Dose Simulator High Throughput (SHEDS-HT) Near-Field Direct (2017)	Isaacs (2017)	7511	Far-Field Industrial and Pesticide
SHEDS-HT Near-field Indirect (2017)	Isaacs (2017)	1119	Residential
Fugacity-based INdoor Exposure (FINE) (2017)	Bennett et al. (2004), Shin et al. (2012)	645	Residential
RAIDAR-ICE Near-Field (0.803)	Arnot et al., (2014), Zhang et al. (2014)	1221	Residential
USEtox Residential Scenario (2.0)	Jolliet et al. (2015), Huang et al. (2016, 2017)	615	Residential
USEtox Dietary Scenario (2.0)	Jolliet et al. (2015), Huang et al. (2016), Ernstoff et al. (2017)	8167	Dietary



Data Curation and Non-Targeted Measurement Methods to Parameterize Exposure Models



Group Type	Documents	Raw Chemical Records	Curated Chemical Records
Consumer Product Composition	473,271	3,738,350	1,791,250
Functional use	33,770	34,680	11,946
CPCat Categories (Public chemical lists)	2,088	117,231	68,133
Occupational exposure	1,304	4,825	1078
Literature monitoring	1,175	966	In process
Habits and practices (Consumer Product Use Patterns)	202	NA	NA



NAM-based Hazard, Toxicokinetic, and Exposure Methods are Beginning to Be Used for Prioritization and Screening-Level Assessments

Federal Register / Vol. 80, No. 118 / Friday, June 19, 2015 / Notices

may claim all or part of a response confidential. EPA will disclose information that is covered by a claim of confidentiality only to the extent permitted by, and in accordance with, the procedures in TSCA section 14 and 45 (CFR part 2).

Public statement: The annual public reporting and recordkeeping burden for this collection of information is estimated to average 21.5 hours per response. Burden is defined in 5 CFR 1220-203.

The ICR, which is available in the docket along with other related materials, provides a detailed explanation of the collection activities and the burden estimate that is only briefly summarized here.

Respondents/Affected Entities: Entities potentially affected by this ICR are companies that manufacture, process or import chemical substances, mixtures or categories.

Estimated total number of potential respondents: 1

Frequency of response: On occasion.

Estimated total average number of responses for each respondent: 1.

Estimated total annual burden hours: 21.5 hours.

Estimated total annual costs: \$2,388. This includes an estimated burden cost of \$2,388 and an estimated cost of \$0 for capital investment or maintenance and operational costs.

III. Are There Changes in the Estimates from the Last Approval?

There is a decrease of 916 hours in the total estimated respondent burden compared with that identified in the ICR currently approved by OMB. This decrease reflects additional both adjustment changes from a reduction in the annual number of PAB reports filed annually, and program changes resulting from mandatory electronic submission of PAB reports. In recent years (FY 2011–FY 2014), EPA has received no PAB submissions and, for the purposes of this analysis, EPA assumes an annual rate of one submission per year. At the time OMB last reviewed this ICR, EPA estimated an average of 23 reports from 14.8 submitors based on fiscal year 2006–2010 data. The ICR supporting statement provides a detailed analysis of the change in burden estimate. This change is both an adjustment and a program change.

IV. What is the Next Step in the Process for this ICR?

EPA will consider the comments received and amend the ICR as appropriate. The final ICR package will then be submitted to OMB for review and approval pursuant to 5 CFR 1320.13. EPA will issue another Federal Register document pursuant to 5 CFR 1320.50(d)(1)(i) to announce the submission of the ICR to OMB and the opportunity to submit additional comments to OMB. If you have any questions about this ICR or the approval process, please contact the technical person listed under FOR FURTHER INFORMATION CONTACT.

Authority: 44 U.S.C. 3503 et seq. 1320-203.

James Jones,
Assistant Administrator, Office of Chemical Safety and Pollution Prevention.
(P) Doc. 2015-1040 (E) 6-18-15; 6-6-15
RL:RJC DOE-000-00-0

ENVIRONMENTAL PROTECTION AGENCY
(EPA-HQ-OPPT-2015-0306; FRL-9928-04)

Use of High Throughput Assays and Computational Tools: Endocrine Disruptor Screening Program; Notice of Availability and Opportunity for Comment

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: This document describes how EPA is planning to incorporate an alternative scientific approach to screen chemicals for their ability to interact with the endocrine system. This will improve the Agency's ability to fulfill its statutory mandate to screen pesticide chemicals and other substances for their ability to cause adverse effects by their interaction with the endocrine system.

The approach incorporates high throughput assay computational model current research, and an alternative for some chemicals in the Endocrine Disruptor Screening Program (EDSP) battery. EPA has past results for over 1000 chemicals have been evaluated a throughput assay as a model for the estrogen pathway. In the future, that additional data will be available for EDSP screening based on the advancement of high and computational model endocrine pathways.

alternative methods a pace of screening, decrease animal burden, and reduce adverse effects on sensitive, specific, and

Agency Issue Paper:

Use of New Approach Methodologies to Derive Extrapolation Factors and Evaluate Developmental Neurotoxicity for Human Health Risk Assessment

NEW APPROACH METHODS AND REDUCING THE USE OF LABORATORY ANIMALS FOR CHRONIC AND CARCINOGENICITY TESTING

Office of Chemical Safety and Pollution Prevention in collaboration with the Office of Research and Development

EPA
United States
Environmental Protection
Agency

New Approach Methods Work

Reducing use of animals in chemical testing

U.S. Environmental Protection Agency
Office of Research and Development
Office of Chemical Safety and Pollution Prevention

June 2020

EPA
United States
Environmental Protection
Agency

Office of

A Working Approach for Identifying Potential Candidate Chemicals for ICR

September 2018

Table 2. Initial Selection of On-Going EPA Case Studies for Potential Incorporation into Work Plan

Title	Description
Refining Inhalation Risk Assessment with NAMs	Refine inhalation risk assessment for point of contact toxicity using a three-dimensional <i>in vitro</i> test system of human respiratory tissues to derive a point of departure, in conjunction with computational fluid dynamic modeling.
Integrating <i>In Vitro</i> Assay and Toxicokinetic Data in Read Across	Use of <i>in vitro</i> toxicity and toxicokinetic testing to refine/support read across categories for per- and polyfluoroalkyl substances (PFAS).
Application of <i>In Vitro</i> Bioactivity for Screening-Level Risk Decisions	Use of bioactivity from <i>in vitro</i> assays and <i>in vitro</i> toxicokinetics to prioritize chemical contaminants in biosolids.
Application of NAMs for Chronic and Carcinogenicity Testing	Integration of NAMs to identify chronic toxicity and non-genotoxic carcinogenicity modes-of-action and quantitative points-of-departure for regulatory decisions

Chemicals Management Plan (CMP) Science Committee Objectives Paper
Meeting #5; 16-17 November 2016
Integrating New Approach Methodologies within the CMP: Identifying Priorities for Risk Assessment, Existing Substances Risk Assessment Program

Contents

- 1.0 Meeting Objectives 2
- 2.0 Towards a Roadmap for Integrating NAM into the Risk Assessment Program 2
- 2.1 Conceptual Strategies for Incorporating NAM for Priority-Setting/Risk Assessment 4
- 2.2 Example of a Specific NAM-based Tool 6
- 3.0 Identification of Risk Assessment Priorities 7
- 3.1 Historical and Current Process 7

Overview of key elements in Health Canada SciAD

APCRA Workflow

- Step 1: Extract ToxCast AC₅₀ distribution from active assays (μM)
- Step 2: Apply assay filtering criteria
- Step 3: Calculate 5th percentile of AC₅₀ distribution "bioactivity threshold"
- Step 4: Apply high-throughput toxicokinetic (HTTK) modelling to get administered equivalent dose (AED) (mg/kg-bw/day)

CMP Assessments (N=46)

- Extract NO(A)ELs and LO(A)ELs
- Label PODs:
 - Minimum
 - Risk characterization
 - Effect Type
 - systemic
 - developmental
 - reproductive

POD_{Bioactivity} ↔ **POD_{Traditional}**

"Comparison Case Study"

Health Canada CMP Screening Assessments

https://www.epa.gov/sites/production/files/2020-01/documents/6_508_tara_barton-maclaren_nams_2019.pdf

Take Home Messages...

- EPA makes a broad range of decisions on chemicals that require different data and levels of certainty
- Most chemicals EPA regulates have limited data on hazard, toxicokinetics, exposure
- EPA is committed to filling data gaps and evaluating chemicals for potential human health and environmental risks while reducing animal testing
- Research on NAMs by both EPA and external groups will play an important role in achieving the Agency's goals
- Use of NAMs in regulatory decisions has increased rapidly over the last 5 years

Questions?